Management of Allergic Rhinitis Inadequately Controlled by Montelukast

Introduction to Intranasal Corticosteroids

The American Academy of Otolaryngology-Head and Neck Surgery recommends switching from montelukast to an intranasal corticosteroid for controlling all four major symptoms of allergic rhinitis, as they are the most effective medication class, with strong evidence supporting their superiority over leukotriene receptor antagonists 1, 2
Intranasal corticosteroids are significantly more effective than montelukast for reducing nasal symptoms, including congestion, rhinorrhea, sneezing, and nasal itching, with clinically meaningful differences demonstrated across multiple trials 1, 2, 3

The Joint Task Force on Practice Parameters strongly recommends intranasal corticosteroids over leukotriene antagonists, based on high-quality evidence, for the treatment of allergic rhinitis 1, 2
Start fluticasone propionate 200 mcg once daily, or equivalent intranasal corticosteroid, for the treatment of allergic rhinitis, with expected symptom improvement within 12 hours 5, 6
If nasal congestion is severe, consider using a short course of topical nasal decongestant spray initially, then discontinue to avoid rhinitis medicamentosa 5, 6

Add intranasal antihistamine, such as azelastine, to the intranasal corticosteroid, rather than adding an oral antihistamine, for moderate to severe symptoms not adequately controlled by intranasal corticosteroid monotherapy, as combination intranasal therapy provides superior symptom control compared to either agent alone 1, 2, 7
Combination products, such as fluticasone propionate 200 mcg + azelastine 548 mcg, are available for improved convenience and adherence 1, 2

Montelukast addresses only one inflammatory pathway, while intranasal corticosteroids have broad anti-inflammatory effects controlling multiple mediators, making them a more effective treatment option for allergic rhinitis 5
Do not add montelukast to an intranasal corticosteroid, as it provides no additional benefit, and do not use systemic corticosteroids for routine allergic rhinitis management, reserving them for very severe or intractable symptoms 6, 9
Avoid prolonged use of topical decongestants beyond 3-5 days to prevent rhinitis medicamentosa, and consider allergy testing to identify specific allergens for targeted avoidance strategies and to guide immunotherapy decisions 4, 5, 6

If symptoms remain inadequately controlled despite optimal pharmacotherapy, refer for allergen immunotherapy, which can provide long-term disease modification, and assess and document associated conditions, such as asthma and atopic dermatitis, for concurrent management 4
Consider allergy testing, such as skin or blood IgE testing, to identify specific allergens and guide immunotherapy decisions, and reassure patients that intranasal corticosteroids at recommended doses do not cause clinically significant systemic side effects in adults 4, 5